<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>The Ozempic Aftermath: Why 67% Regain the Weight — And What You Can Do About It – Élan Clinic</title>
  <meta name="description" content="Approximately two-thirds of people who stop GLP-1 medications regain significant weight. A physician explains the biology behind the 67% statistic — and what actually shifts the odds." />
  <link rel="canonical" href="https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back-67-percent.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back-67-percent.html" />
  <meta property="og:title" content="The Ozempic Aftermath: Why 67% Regain the Weight — And What You Can Do About It" />
  <meta property="og:description" content="Approximately two-thirds of people who stop GLP-1 medications regain significant weight. A physician explains the biology and what actually shifts the odds." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "The Ozempic Aftermath: Why 67% Regain the Weight — And What You Can Do About It",
    "headline": "The Ozempic Aftermath: Why 67% Regain the Weight — And What You Can Do About It",
    "url": "https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back-67-percent.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "Approximately two-thirds of people who stop GLP-1 medications regain significant weight. A physician explains the biology behind the 67% statistic — and what actually shifts the odds.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/ozempic-aftermath-why-weight-comes-back-67-percent.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)",
        "isPartOf": { "@type": "Periodical", "name": "New England Journal of Medicine" },
        "datePublished": "2021"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4)",
        "isPartOf": { "@type": "Periodical", "name": "JAMA" },
        "datePublished": "2021"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition",
        "isPartOf": { "@type": "Periodical", "name": "Obesity" },
        "datePublished": "2016"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body { font-family: 'Inter', sans-serif; background-color: #0D1B2A; color: rgba(232, 228, 222, 0.55); line-height: 1.7; -webkit-font-smoothing: antialiased; }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">The Ozempic Aftermath</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Weight Regain</span>
        <h1>The Ozempic Aftermath: Why 67% Regain the Weight — And What You Can Do About It.</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            14 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"We are more often frightened than hurt; and we suffer more from imagination than from reality." — Seneca. True enough — but sometimes the fear is well-founded. And sometimes, understanding the thing that frightens us is the only way through it.</p>
        </div>

        <p>
          You've probably seen the headlines. Maybe you've lived them.
        </p>

        <p>
          Someone loses 20 kilograms on Ozempic or Wegovy. They feel transformed. Then, for whatever reason — cost, side effects, a doctor's advice, a personal decision — they stop. And the weight comes back. Not all of it, sometimes. But most of it, usually. And sometimes more than they lost.
        </p>

        <p>
          Whatever you call it, the data is clear and consistent: approximately two-thirds of people who stop GLP-1 medications like semaglutide regain a significant portion of the weight they lost. And that number — 67% — deserves an honest explanation, not a headline.
        </p>

        <hr />

        <h2>What the Research Actually Shows</h2>

        <p>
          The STEP 1 trial, published in the <em>New England Journal of Medicine</em> in 2021, showed that weekly semaglutide 2.4mg produced an average weight loss of 14.9% of body weight over 68 weeks. But the STEP 1 extension study is equally important: when participants stopped the drug and returned to lifestyle intervention alone, they regained an average of two-thirds of that lost weight within one year.
        </p>

        <p>
          The STEP 4 trial went further. It was specifically designed to test what happens when you stop. After 20 weeks of semaglutide, participants were randomized to either continue the drug or switch to placebo. Over the following 48 weeks, the withdrawal group regained 6.9% of their body weight. The continuation group lost a further 7.9%. That's a nearly 15-percentage-point divergence from a single variable: continuation versus cessation.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">67%</div>
          <div class="key-stat__label">Average proportion of lost weight regained within one year of stopping semaglutide — not a failure of willpower, but a predictable biological response to treating a chronic condition and then stopping treatment.</div>
        </div>

        <p>
          The conclusion that emerges from this body of evidence is one that makes some people uncomfortable: for most people, these medications need to be continued long-term to maintain their effects. Not because the drugs are addictive. Not because the patients are weak. But because obesity is a chronic, biologically driven condition — and the medications are treating it, not curing it.
        </p>

        <hr />

        <h2>Why the Weight Comes Back: The Biology Nobody Explains</h2>

        <p>The 67% statistic gets reported. What rarely gets reported is <em>why</em>.</p>

        <p>
          <strong>Your brain defends a set point.</strong> The hypothalamus functions as a body weight regulator. When body weight drops significantly, the hypothalamus treats this as a threat to survival. It responds by increasing hunger signals and decreasing the rate at which the body burns energy — adaptive thermogenesis: your body becoming more fuel-efficient in response to perceived starvation. GLP-1 medications don't reprogram the set point — they override hunger signals while the drug is active. When the drug is withdrawn, the set point reasserts itself.
        </p>

        <p>
          <strong>Ghrelin surges.</strong> Ghrelin is the body's primary hunger-stimulating hormone. During weight loss, ghrelin levels tend to increase. When you stop a GLP-1 medication, ghrelin doesn't simply return to its pre-treatment level. There's evidence of a rebound effect, where ghrelin temporarily overshoots baseline. This means hunger after stopping may feel more intense than it did before you ever started treatment.
        </p>

        <p>
          <strong>Metabolic rate drops — and doesn't fully recover.</strong> The famous <em>Biggest Loser</em> follow-up study (Fothergill et al., <em>Obesity</em>, 2016) found that contestants who lost dramatic amounts of weight had metabolic rates hundreds of calories below predictions even years later — regardless of how much weight they'd kept off. GLP-1 cessation creates a similar dynamic: your body burns less than it "should" for its size, while simultaneously sending stronger hunger signals.
        </p>

        <p>
          <strong>Lean mass is lost, and fat mass returns.</strong> Weight loss on semaglutide isn't purely fat loss. Studies show that 25–40% of weight lost on GLP-1 medications comes from lean mass. When weight returns, it tends to come back preferentially as fat. This means body composition can worsen even if the scale eventually settles at a similar number to before treatment began.
        </p>

        <hr />

        <h2>Who Regains the Most — and Who Regains the Least</h2>

        <p>
          <strong>Lifestyle integration.</strong> People who used the appetite suppression window to build genuine behavioral changes — regular exercise, higher protein intake, structured eating patterns — tend to regain less. The drug reduces hunger; what you build while hunger is reduced can persist after the drug is gone.
        </p>

        <p>
          <strong>Lean mass preservation.</strong> Those who engaged in resistance training during treatment maintained more muscle, which correlates with better metabolic resilience after stopping.
        </p>

        <p>
          <strong>Psychological relationship with food.</strong> Emotional eating patterns, food anxiety, and disordered eating behaviors don't resolve with a medication. If those patterns were present before, they return — sometimes amplified — when the appetite-dampening effect of semaglutide disappears.
        </p>

        <hr />

        <h2>The Conversation Nobody's Having</h2>

        <p>
          GLP-1 medications were never designed to be finite interventions with permanent effects. They were designed to treat a chronic condition — and like most chronic disease treatments, they work while you take them.
        </p>

        <div class="pull-quote">
          <p>When we treat hypertension, we don't expect patients to take medication for 5 years and then be "cured." The same logic applies here — but somewhere in the rollout of GLP-1 medications, the expectation that they'd produce durable changes after discontinuation took hold. It was never realistic.</p>
        </div>

        <p>
          The result: patients stop, weight returns, and they feel like they've failed. They haven't. The system failed to set appropriate expectations.
        </p>

        <hr />

        <h2>What You Can Actually Do</h2>

        <p>
          <strong>1. Don't stop without a plan.</strong> If you're considering stopping GLP-1 therapy, do it in consultation with a physician who can help you build a structured transition. The biology is most aggressive in the first 3 months post-cessation; having support during that window is genuinely important.
        </p>

        <p>
          <strong>2. Start resistance training before you stop.</strong> If you're still on medication and know you'll eventually need to stop, begin building muscle now. Every kilogram of lean mass you preserve or build is insurance against post-cessation metabolic adaptation. Progressive resistance training 2–3 times per week is the most evidence-backed approach.
        </p>

        <p>
          <strong>3. Prioritize protein — significantly more than you think.</strong> Research consistently shows that higher protein intake during weight loss preserves lean mass and increases satiety. Target 1.2–1.6g per kilogram of body weight daily. Most people eat less than half this.
        </p>

        <p>
          <strong>4. Understand the hunger surge and prepare for it.</strong> Knowing that ghrelin may temporarily overshoot baseline means you can prepare behavioral strategies in advance: structured meal timing, protein-forward meals, minimizing food cue exposure, and having a plan for the moments when hunger feels overwhelming.
        </p>

        <p>
          <strong>5. Consider maintenance dosing.</strong> Some patients and clinicians are exploring reduced-dose maintenance strategies — continuing semaglutide at a lower dose as a longer-term maintenance approach. This is an evolving area of practice, not yet standardized, and requires individual clinical assessment.
        </p>

        <p>
          <strong>6. Address what the medication couldn't touch.</strong> Stress. Sleep. Insulin resistance. Emotional eating. These are often the underlying drivers of the weight that medication helped suppress. They don't go away when the medication does.
        </p>

        <p>
          <strong>7. Reframe "regain" as information, not failure.</strong> Weight returning after stopping a medication tells you something true about your physiology: that you were treating a chronic condition that persists when treatment stops. That's data, not defeat.
        </p>

        <hr />

        <h2>The Harder Truth About Long-Term Weight Management</h2>

        <p>
          There's no intervention — dietary, pharmaceutical, or surgical — that works for everyone, permanently, without ongoing effort or treatment. The biology of body weight regulation is extraordinarily powerful, and it runs in the direction of weight preservation, not weight loss.
        </p>

        <p>
          What GLP-1 medications have shown us is that this biology is modulatable — that with the right pharmacological tool, the hunger and reward systems can be reset enough to produce clinically significant, health-improving weight loss. That is genuinely new, and genuinely important.
        </p>

        <p>
          What the aftermath data shows us is that this modulation requires ongoing input. The question "can I come off the medication eventually?" is completely legitimate — and for some people, the answer may be yes, particularly those who have made deep, durable changes to lifestyle, body composition, and metabolic health during treatment.
        </p>

        <p>
          But the answer shouldn't be assumed. It should be tested carefully, with support, and with eyes open to the biology.
        </p>

        <hr />

        <h2>If You're Navigating This Right Now</h2>

        <p>
          If you're watching the weight return and wondering where you went wrong: you probably didn't go wrong. You stopped treating a condition, and the condition reasserted itself. That's not a character flaw.
        </p>

        <p>
          What matters now is what you do with this understanding. A good medical evaluation — one that looks at your full metabolic picture, your body composition, your hormonal environment, and your history — is the starting point. There are more options available today than there were even three years ago.
        </p>

        <p>You don't have to navigate this alone, and you don't have to accept weight regain as inevitable.</p>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." <em>New England Journal of Medicine</em>, 2021 (STEP 1).</p>
          <p>Rubino DM et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." <em>JAMA</em>, 2021.</p>
          <p>Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." <em>New England Journal of Medicine</em>, 2022 (SURMOUNT-1).</p>
          <p>Fothergill E et al. "Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition." <em>Obesity</em>, 2016.</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Navigating Life After GLP-1 Therapy?</h2>
    <p class="footer-cta__sub">
      A structured medical evaluation covering your full metabolic picture, body composition, and post-cessation transition plan — before you stop, not after.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
